MAZE
VENTE TOTALE: 22 638 titres (~592 961,12 $ US)
- Insiders
- Coloma Jason V
- Total bought
- —
- Total sold
- $592,961
- Last activity
- 2026-09-03
- Last synced
-
2026-09-09 09:58:02
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-08
MAZE presents a critically deteriorated fundamental profile with zero revenue and negative operating cash flow in 2025, rendering its high liquidity ratio a misleading signal of operational health.
The first sentence of the analysis written for MAZE on 2026-09-08 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 100.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 31.9% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 33.9% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 34.4% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 31.9% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 31.2% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 31.2% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 2.0% | 0.0% | 0.0% | |
| Current Ratio | 15.504 | 9.755 | 2.091 | 5.107 | |
| Quick Ratio | 15.504 | 9.755 | 2.091 | 5.107 | |
| Solvency Ratio | -3.053 | 1.272 | -1.568 | -2.290 | |
| Cash Ratio | 8.390 | 9.520 | 1.787 | 4.808 | |
| Price To Earnings Ratio | -13.584 | 205.013 | -6.954 | -6.075 | |
| Price To Earnings Growth Ratio | 0.003 | -1.983 | 0.550 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.003 | -1.983 | 0.550 | 0.000 | |
| Price To Earnings Diluted Ratio | -13.584 | 205.013 | -6.954 | -6.075 | |
| Price To Earnings Diluted Growth Ratio | 0.003 | -1.983 | 0.550 | 0.000 | |
| Price To Book Ratio | 5.016 | 3.548 | 69.449 | 6.883 | |
| Price To Sales Ratio | 0.000 | 4.170 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -15.794 | 9.338 | -8.001 | -6.902 | |
| Price To Operating Cash Flow Ratio | -15.906 | 9.197 | -8.042 | -7.039 | |
| Debt To Assets Ratio | 0.059 | 0.111 | 0.694 | 0.214 | |
| Debt To Equity Ratio | 0.066 | 0.135 | 4.936 | 0.316 | |
| Debt To Capital Ratio | 0.062 | 0.119 | 0.832 | 0.240 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.666 | 0.000 | |
| Financial Leverage Ratio | 1.119 | 1.222 | 7.112 | 1.478 | |
| Working Capital Turnover Ratio | 0.000 | 1.685 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.963 | 3.674 | -5.322 | -4.773 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.453 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | 0.985 | 1.005 | 1.020 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -4.803 | 2.852 | -1.750 | -3.095 | |
| Capital Expenditure Coverage Ratio | -140.982 | 66.220 | -196.887 | -50.459 | |
| Dividend Paid And Capex Coverage Ratio | -140.982 | 66.220 | -196.887 | -50.459 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.543 | 9.319 | -7.461 | -5.673 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▼-100.0% | ▼-25.0% |
| Ebit Margin | 0.0% | ▼-31.9% | ▼-8.0% |
| Ebitda Margin | 0.0% | ▼-33.9% | ▼-8.5% |
| Operating Profit Margin | 0.0% | ▼-34.4% | ▼-8.6% |
| Pretax Profit Margin | 0.0% | ▼-31.9% | ▼-8.0% |
| Continuous Operations Profit Margin | 0.0% | ▼-31.2% | ▼-7.8% |
| Net Profit Margin | 0.0% | ▼-31.2% | ▼-7.8% |
| Bottom Line Profit Margin | 0.0% | ▼-2.0% | ▼-0.5% |
| Current Ratio | 15.504 | ▲5.749 | ▲7.390 |
| Quick Ratio | 15.504 | ▲5.749 | ▲7.390 |
| Solvency Ratio | -3.053 | ▼-4.325 | ▼-1.643 |
| Cash Ratio | 8.390 | ▼-1.130 | ▲2.264 |
| Price To Earnings Ratio | -13.584 | ▼-218.596 | ▼-58.184 |
| Price To Earnings Growth Ratio | 0.003 | ▲1.986 | ▲0.361 |
| Forward Price To Earnings Growth Ratio | 0.003 | ▲1.986 | ▲0.361 |
| Price To Earnings Diluted Ratio | -13.584 | ▼-218.596 | ▼-58.184 |
| Price To Earnings Diluted Growth Ratio | 0.003 | ▲1.986 | ▲0.361 |
| Price To Book Ratio | 5.016 | ▲1.468 | ▼-16.208 |
| Price To Sales Ratio | 0.000 | ▼-4.170 | ▼-1.043 |
| Price To Free Cash Flow Ratio | -15.794 | ▼-25.132 | ▼-10.454 |
| Price To Operating Cash Flow Ratio | -15.906 | ▼-25.103 | ▼-10.459 |
| Debt To Assets Ratio | 0.059 | ▼-0.052 | ▼-0.211 |
| Debt To Equity Ratio | 0.066 | ▼-0.070 | ▼-1.298 |
| Debt To Capital Ratio | 0.062 | ▼-0.058 | ▼-0.252 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.167 |
| Financial Leverage Ratio | 1.119 | ▼-0.103 | ▼-1.614 |
| Working Capital Turnover Ratio | 0.000 | ▼-1.685 | ▼-0.421 |
| Operating Cash Flow Ratio | -4.963 | ▼-8.637 | ▼-2.117 |
| Operating Cash Flow Sales Ratio | 0.000 | ▼-0.454 | ▼-0.113 |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | ▲0.022 | ▲0.003 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -4.803 | ▼-7.655 | ▼-3.104 |
| Capital Expenditure Coverage Ratio | -140.982 | ▼-207.202 | ▼-60.455 |
| Dividend Paid And Capex Coverage Ratio | -140.982 | ▼-207.202 | ▼-60.455 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.543 | ▼-21.862 | ▼-8.454 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $1.78B | $698.5M | $698.2M | $698.2M | |
| Enterprise value | $1.61B | $528.4M | $718.7M | $630.4M | |
| EV / Sales | 0.00x | 3.15x | 0.00x | 0.00x | |
| EV / Op. cash flow | -14.42x | 6.96x | -8.28x | -6.35x | |
| EV / Free cash flow | -14.32x | 7.06x | -8.24x | -6.23x | |
| EV / EBITDA | -12.54x | 9.32x | -7.46x | -5.67x | |
| Net debt / EBITDA | 1.29x | -3.00x | -0.21x | 0.61x | |
| Current ratio | 15.50x | 9.76x | 2.09x | 5.11x | |
| Income quality | 0.85x | 1.45x | 0.86x | 0.86x | |
| Graham number | — | $11 | — | — | |
| Graham net-net | $7 | $3 | -$1 | $1 | |
| Tax burden | 100.0% | 97.8% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $327.2M | $181.0M | $17.8M | $85.4M | |
| Invested capital | $352.3M | $210.9M | $52.8M | $126.6M | |
| Return on assets | -33.0% | 21.7% | -140.4% | -76.6% | |
| Operating ROA | -44.8% | 36.9% | -89.0% | 0.0% | |
| Return on tangible assets | -33.0% | 21.7% | -140.4% | -76.6% | |
| Return on equity | -36.9% | 26.5% | -998.8% | -113.3% | |
| Return on invested capital | -37.7% | 25.1% | -165.1% | -83.2% | |
| Return on capital employed | -38.2% | 26.2% | -178.6% | -86.0% | |
| Earnings yield | -7.4% | 7.5% | -14.4% | -16.5% | |
| Free cash flow yield | -6.3% | 10.7% | -12.5% | -14.5% | |
| Capex / Op. cash flow | -0.7% | 1.5% | -0.5% | -2.0% | |
| Capex / Depreciation | 33.0% | 34.8% | 10.8% | 51.5% | |
| Capex / Sales | 0.0% | 0.7% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 15.8% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 49.8% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 5.8% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 272d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -272d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+154.9%EV / Sales ▼-100.0%EV / EBITDA ▼-234.6%EV / Op. cash flow ▼-21.380Earnings yield ▼-0.148
Profitability
Return on equity ▼-0.635Return on assets ▼-0.547Return on invested capital ▼-0.628Return on capital employed ▼-0.643Operating ROA ▼-0.817Income quality ▼-0.600Tax burden ▲+0.022
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-0.007R&D / Sales ▼-0.498
Balance-sheet strength
Current ratio ▲+5.749Net debt / EBITDA ▲+4.291Working capital ▲+146163000.000Invested capital ▲+141405000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+155.0%EV / Sales n/aEV / EBITDA ▼-121.1%EV / Op. cash flow ▼-8.069Earnings yield ▲+0.091
Profitability
Return on equity ▲+0.764Return on assets ▲+0.436Return on invested capital ▲+0.455Return on capital employed ▲+0.478Operating ROA n/aIncome quality ▼-0.009Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+10.397Net debt / EBITDA ▲+0.678Working capital ▲+241795000.000Invested capital ▲+225727000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-07 Maze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest Position Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 10.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,032,915 shares of the company''s stock after acquiring an additional 465,641 shares during the period. Maze Therapeutics accounts
- 2026-09-02 Maze Therapeutics to Participate in Three Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m.
- 2026-08-30 BlackRock Inc. Purchases Shares of 3,502,841 Maze Therapeutics, Inc. $MAZE BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,502,841 shares of the company''s stock, valued at approximately $104,525,000. BlackRock Inc. owned approximately 6.33% of Maze Therapeutics as
- 2026-08-27 Bank of America Corp DE Purchases 176,703 Shares of Maze Therapeutics, Inc. $MAZE Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 961.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 195,084 shares of the company''s stock after buying an additional 176,703 shares during the period. Bank of America Corp DE
- 2026-08-26 Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex''s inaxaplin; pivotal trials are planned for 1H 2027.
- 2026-08-26 ARCH Venture Management LLC Makes New $122.98 Billion Investment in Maze Therapeutics, Inc. $MAZE ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,120,053 shares of the company''s stock, valued at approximately $122,983,582,000. Maze Therapeutics accounts for about 11.2% of ARCH Venture Management
- 2026-08-13 Maze Therapeutics Announces Appointments to Its Board of Directors Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze''s Board of Directors, adding to the Company''s deep bench of clinical and industry experience
- 2026-08-11 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the second quarter ended June 30, 2026, highlighting recent progress and business updates.
- 2026-07-21 Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect? The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-06-29 What Does the Maze Therapeutics CEO''s Sale of Nearly 30,000 Shares Mean for Investors? This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.